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ABSTRACT
OBJECTIVE:
The objective of this selective EBM review is to determine whether or not daily intake of
glucosamine supplements prevents the need for knee replacements later in life for adults
predisposed to osteoarthritis.
STUDY DESIGN:
Review of three English language primary randomized controlled trial studies published
between 2001 and 2008
DATA SOURCES:
Three double blind randomized control trials comparing glucosamine supplements to
placebo were found using PubMed.
OUTCOMES MEASURED:
Outcomes were measured using radiographic studies of the knees, joint space
measurements, and symptoms were evaluated using Lequesne and WOMAC indexes.
RESULTS:
The Reginster (2001) and Pavelka (2002) studies demonstrated no change in joint space
measurements in the experimental glucosamine group and a 20-25% decrease in
symptoms such as pain and stiffness in the Pavelka study. In the Bruyere (2008) study, 19
out of 131 (14.5%) of those in the placebo group underwent total joint replacement five
years after the trial and 9 out of 144 (6.3%) of those in the experimental glucosamine
group underwent total joint replacement five years after the trial.
CONCLUSIONS:
The three randomized controlled trial in this review concluded that glucosamine
supplements retard the progression of joint space narrowing and will delay the need for a
total joint replacement up to five years after discontinuing glucosamine supplements.
KEY WORDS:
Glucosamine, Osteoarthritis, joint space narrowing, total joint replacements
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Introduction
Knee Osteoarthritis (OA) is the most common form of osteoarthritis and fifth
leading cause of disability in the United States1. The only cure for knee OA is total joint
replacement (TJR). Knee osteoarthritis is conventionally managed symptomatically using
anti-inflammatory medication such as naproxen and over-the-counter (OTC) pain
medications. Unlike Rheumatoid arthritis, there is not a disease modifying medication,
like the DMARD class of medication, for osteoarthritis. Thus, healthcare providers are
treating the symptoms without slowing the progression of cartilage breakdown. As the
patient’s function deteriorates further, symptomatic treatment becomes ineffective and
TJR is warranted. Glucosamine supplements have been advertised as OTC supplements
for alleviating joint pain and promoting joint health. Research has shown that
glucosamine supplements have the potential of slowing down the progression of joint
space narrowing when compared to placebo while improving OA symptoms and
restoring function.
The use of glucosamine supplements in the management of OA is relevant to
patients and the physician assistant (PA) practice because managing OA can be a
financial burden on the patient and the loss of function can be life changing.
Approximately 27 million Americans suffer from OA1. In the western world, 5-15% of
people 35-74 years of age will have radiographic changes on knee studies such as joint
space narrowing2. Since OA is common, the cost of management and treatment is a
burden on society. In 2007, the cost for arthritis was $128 billion per year in medical
care and indirect expenses such as lost wages3. As of 2004, the total annual cost of OA
per person was estimated to be $57003. As for the number of visits per year, in 1993, it
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was estimated that an OA patient schedules 3.3 office visits per year1. Current data is
unavailable due to the type of management the patient is seeking (such as injections,
post-op, etc).
Osteoarthritis is a degenerative progressive condition characterized by joint pain,
joint stiffness after activities, as well as osteophyte formation seen on radiographic
studies. It also includes the breakdown of cartilage in the joints which causes the
symptoms mentioned above. The exact cause of osteoarthritis is unknown and therefore
thought to be idiopathic. However, it is associated with obesity, repetitive motion,
injuries, and aging.
As mentioned above, OA is treated symptomatically with analgesics such as
Tylenol. Synovial joint injections are also used lubricate the knee and prevent the “boneon-bone” rubbing due to cartilage lose. Physical and occupational therapy as well as
weight reduction are also implemented in the management of OA3.
Currently, TJR is the definitive cure for knee arthritis. Not all of those affected by
OA are eligible for TJR. In general, the surgeon considers the patient’s health, severity of
the symptoms, extend of the disability, as well as age. Surgeons are less likely to perform
TJR on a younger person, less than 65 years old, due to the life-expectancy of the
prosthetic components—a younger person will more likely have to undergo a revision
surgery later on in life to replace worn out prosthetic components. The revision surgery
is more difficult than TJR and carries more risks and complications as well. Therefore, a
supplement with disease retarding capability will benefit the patients and reduce the
number of procedures they may undergo in their lifetime. Glucosamine sulfate has been
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shown to slow down the progression of knee arthritis and preserving the joint space.
Since the joint space is maintained, the patients’ symptoms lessen in severity or even
cease. Thus restoring function and productivity as well as delaying the need for a surgical
intervention such as a total joint replacement. This eliminates the financial burden of
having multiple surgical interventions and improving the patients’ quality of life.
Objective:
The objective of this selective EBM review is to determine whether or not daily
intake of glucosamine supplements prevents the need for knee replacements later in life
of adults predisposed to osteoarthritis.
Methods:
Studies were selected based on population and type of intervention. The studies
selected focused on adults over 18 years of age with OA symptoms. The intervention
was oral glucosamine supplements. The studies compared the treatment group which
received 1500mg of oral glucosamine supplements daily and the control group which
received a placebo daily. The outcomes were measured using radiographic imaging to
measure the joint space. The tibiofemoral joint space was measured and compared to the
measurement taken prior to the start of the trial. Symptoms were assessed using algofunctional indexes of Lequesne and WOMAC. All three studies were randomized placebo
controlled trials.
A detailed search using PubMed and EBSCOhost was conducted using
glucosamine supplements and knee osteoarthritis as keywords. All of the articles found
and used in this review were published in peer-reviewed journals and written in English

Helmy, OA: Glucosamine Preventing TJR, 5
between 2001 and 2008. The author of this review conducted the research and selected
the studies based on the relevance and on the importance of outcomes to the patients
(POEMS). The inclusion criteria were randomized controlled double blind studies
performed after 1996 using glucosamine as an intervention. The exclusion criteria were
patients over the age of 18, patients with hip arthritis, and using chondroitin as an
intervention. The statistics reported and used were 95% confidence intervals, numbersneeded to harm (NNH), and p-values.
Table 1: Demographics and characteristics of included studies
Study
Pavelka1
(2002)

Type

#
Age Inclusion
pt
criteria
Double 202 45- Primary knee
blind
70
OA
RCT
-diagnoses
based on
clinical and
radiological
criteria of the
American
College
of
Rheumatology
-minimum
score of 4 on
Lequesne
index

Reginster4 Double 212 >50
(2001)
blind
RCT

Primary knee
OA and over
age 50

Exclusion
criteria
-Lequesne
score of 12
- history of
articular and
rheumatic
diseases other
than OA
- history of
traumas or
lesions of the
knee
-severe
articular
inflammation
- rapidly
progressive
osteoarthritis
-overweight
(BMI >27).
- systemic or
intra-articular
corticosteroid
use 3 months
prior to trial.
-history or
active
presence of

W/D Intervention
81

1500mg
glucosamine
sulfate PO
QD x 3 years

73

1500mg
glucosamine
sulfate PO
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Bruyere5
(2008)

Double 275 40blind
70
RCT

Participation
in 3 year trial
in the past

other
rheumatic
diseases
-severe
articular
inflammation
-traumatic
knee lesions
-overweight
(BMI >30)
-intra-articular
or systemic
corticosteroids
in the 3
months prior
to trial
Had TKR
surgery after
pervious trial

QD x 3 years

0

Followed for
incidence of
TJR

Outcomes measured:
The outcomes measured were patient oriented evidence that matters (POEMs).
The objective data was measured using radiographic studies. The radiographic studies
were conducted at the time of enrollment, after one year of treatment, and after 3 years of
treatment. The medial joint space of the knee was then measured. To assess the
symptoms, the Reginster et. al study used WOMAC while the Pavelka et. al used
Lequesne and WOMAC. The Western Ontario and McMaster Universities Arthritis
Index (WOMAC) is used to assess the severity of arthritis related symptoms such as pain
(score from 0-20), stiffness (score 0-8), and function limitations (score 0-68)4. The
Lequesne Algo-functional index measures pain, distance walked, and activities of daily
living5.
Results:
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In Pavelka, et. al, there was progressive joint space loss in the placebo group
while there was no progression in joint space narrowing in the glucosamine group. At the
end of the 3 year trial, there was 0.36mm difference in joint space between the two
groups with 95% confidence interval of 0.13-0.59mm and a p-value <0.001.2
Table 2: Intent-to-Treat Cumulative Joint Space Narrowing (in mm) at Each Year of
Treatment
Year
1
2
3

Placebo
-0.04
-0.08
-0.19

Glucosamine
-0.05
-0.03
-0.04

Difference
0.097
0.11
0.23

p-Value
0.049
0.030
0.001

As for the symptoms, the glucosamine group had a 20%-25% score reduction on the
WOMAC and Lequesne indexes with p-value of 0.02 for WOMAC and <0.001 for
Lequesne. In addition, the joint stiffness subscale of the WOMAC had a significant
reduction in the glucosamine group with -0.31 95% confidence interval (CI) compared to
the placebo group which had 0.11 95% CI. 2 The authors of the study included adverse
events reported by the patients during the three year trial. 66% of the placebo group and
64% of the glucosamine group reported at least one adverse event over the course of the
three years2. The authors did not report significant differences between the groups and the
adverse events reported.
Table 3: Adverse Events reported by participants during the course of the trial2
System Organ Class
Gastrointestinal tract and liver
Musculoskeletal
Cardiovascular
Skin and appendages
Respiratory tract
Urinary tract
Metabolic and nutritional
Other*

Placebo

Glucosamine
28
22
20
15
7
11
6
14

25
30
23
10
17
12
7
14

Helmy, OA: Glucosamine Preventing TJR, 8
* Isolated adverse events : nervous, psychiatric, blood cell disorders, neoplasms, endocrine disorders,
reproductive (male/female), vision disorders, hearing, and vestibular. 2

In Reginster et. al. study, the intention-to-treat analysis showed a lower mean
joint space narrowing in the glucosamine group compared to the placebo group. The
mean joint space narrowing for the glucosamine group was -0.06mm while the placebo
group was -0.31mm with a 95% CI of 0.24 (0.01-0.08) and p-value of 0.043 6. As for the
symptoms, the WOMAC index shows worsening of symptoms in the placebo group by
the end of the three year trial when compared to the glucosamine group. The difference
between the final group averages at the end of the three year period was significant
(p=0.016)6. In addition, the study reports an improvement of function and pain on the
WOMAC subscales in the glucosamine group. The authors of the study noted that there
was improvement of symptoms in the glucosamine group even when the joint space
narrowing was considered severe. With regards to adverse events, most of the
participants reported at least one adverse event, 93% in the placebo group and 94% in the
glucosamine group. The authors did not report any differences between the groups with
regards to frequency of events or type of event 6. The table below is a summary of the
events reported by the participants.
Table 5: Adverse events reported during Reginster et al trial6
Adverse Event
Abdominal pain
Dyspepsia
Diarrhea
Increased blood pressure
Decreased blood pressure
Cardiac failure
Fatigue
Headache
Vertigo
Neuritis
Depressive mood
Allergic episode

Placebo

Glucosamine

18
8
11
15
8
7
7
4
3
6
7
7

13
4
10
15
2
4
10
6
7
4
4
4
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In Bruyere et al study, 19 out of 131 (14.5%) placebo recipients underwent a total
joint replacement surgery within the 5 years following the end of the trial. Only 9 out of
144 (6.3%) glucosamine recipients underwent TJR after the trial. In other words, twice as
many participants in the placebo group underwent TJR compared to the glucosamine
group. The study reported a p-value of 0.024 and relative risk of undergoing TJR of 0.43
(95% CI from 0.20 to 0.92) for the glucosamine group participants—a 57% decrease
compared to the placebo group. The reported NNT to avoid TJR was 12 7. With regards
to adverse events, the authors did not report adverse events during the course of the trial.
Discussion:
The use of glucosamine sulfate supplements as a daily supplement for an
extended period of time has proven effective in delaying the progression of Osteoarthritis
and thus the need to undergo total joint replacement surgeries. Glucosamine sulfate
supplements are readily available over-the-counter in pharmacies, supermarkets, and
health stores such as GNC. After conducting an online price search, the prices of
glucosamine sulfate supplements ranged from $9 to $35. It is considered a relatively safe
supplement with minimal adverse reactions, such as constipation, diarrhea, nausea,
vomiting, and pruritus8. There are no contraindications for glucosamine8. Most of the
studies performed up to this date investigated the effects of glucosamine on patients with
OA. However, there are studies looking at the effects of the compound on weight loss,
glaucoma, multiple sclerosis, and cancer8. Other uses for glucosamine have not been
studied as extensively as the use for OA.
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Some drug interactions were reported for glucosamine sulfate. There is a major
interaction warning for the use of glucosamine with Coumadin9. There has been several
reports of glucosamine increasing the effect of Coumadin thus causing easy bruising and
increasing the risk for serious bleeds. There may be a moderate interaction between
antimitotic chemotherapy and glucosamine. There is a chance that glucosamine may
increase the rate of cell division which may decrease the effectiveness of cancer
medications intended to reduce the rate of cell division in tumors9. In addition,
glucosamine may increase blood sugar levels in diabetics and may decrease the
effectiveness of diabetic medications8,9. Glucosamine is not contraindicated in diabetics
but diabetic patients are advised to monitor their blood sugar levels more cautiously when
taking glucosamine supplements.
The three studies were not limited with regard to sample size and duration of the
trial. However, more studies are necessary to adequately conclude that glucosamine
supplements may have disease-modifying effects on patients with Osteoarthritis. In
addition, the studies should mention the source of glucosamine used in the trial. Since
glucosamine is a supplement, it is not FDA monitored and the purity of the OTC
supplement should be questioned. There have been reports in the media of OTC
supplements with compounds not listed on the bottle which caused adverse events in the
users.
Conclusion:
All three studies have shown that glucosamine did retard the progression of
osteoarthritis in adults with knee arthritis and did delay the need for total joint
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replacement when compared to the placebo group. In addition, those who received
glucosamine reported improvement of OA symptoms such as improved function and
decrease in pain. Future studies are warranted to evaluate the effects of glucosamine
sulfate on young athletes, such as runners and basketball players, who tend to develop
OA symptoms at a young age. The study would include athletes between the ages of 18
and 25 with mild knee pain or previous knee injuries which predispose them to OA. It
would be interesting to see if glucosamine supplements will halt the progression of joint
space narrowing and improve joint function in such active subjects.
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